[Tree] The Surprising Link Between Adenoviruses, Fatty Liver Disease, and Worsening Breast Cancer

Version 0.19 (2024-07-10 02:50:13.517000)

updates: The study conducted by the School of Chinese Medicine at the University of Hong Kong (HKUMed) reveals the link between fatty liver disease and worsening breast cancer

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.18 (2024-07-06 23:58:14.880000)

updates: New research reveals the potential role of adenoviruses in obesity

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.17 (2024-07-06 23:55:52.663000)

updates: Inclusion of new research on the role of adenovirus 36 in obesity

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.16 (2024-06-16 17:24:12.263000)

updates: Inclusion of a study on the relationship between TyG-BMI and mortality in diabetic patients

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.15 (2024-04-04 12:14:58.484000)

updates: Genetic factors driving obesity in China

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.14 (2024-03-18 11:41:43.631000)

updates: Integration of information about managing genetic risks and adopting a healthy lifestyle

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.13 (2024-03-18 02:43:28.694000)

updates: Integration of a recent study on the impact of environmental exposures on chronic diseases in the Chinese population

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.12 (2024-03-14 08:23:07.755000)

updates: Inclusion of a new study on global obesity rates and the obesity economy

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.11 (2024-03-03 13:19:37.860000)

updates: The story has been expanded to include information about the global obesity epidemic, particularly among children and in developing countries.

  • ➔
  • ➔
  • ➔
Version 0.1 (2024-02-20 02:46:32.051000)

updates: China's obesity rates and prevalence of complications

  • ➔
  • ➔
Version 0.09 (2024-02-20 02:06:54.058000)

updates: The rise in obesity in China and the off-label use of Ozempic for weight loss

  • ➔
  • ➔
Version 0.08 (2024-02-20 02:00:26.704000)

updates: China's obesity issue and the gray market for weight-loss drugs

  • ➔
Version 0.07 (2024-02-17 13:53:57.508000)

updates: Added information about the potential mental health benefits of GLP-1 medications

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.06 (2024-02-16 15:55:49.210000)

updates: Updates on the success and impact of GLP-1 weight loss drugs

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.05 (2024-01-25 11:53:07.526000)

updates: Inclusion of concerns about anti-fat discrimination, stigmatization, and the need to consider social and psychological factors in weight loss discourse

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.04 (2024-01-06 10:20:38.559000)

updates: Insurance coverage for weight loss injections

  • ➔
  • ➔
  • ➔
Version 0.03 (2023-12-29 17:48:22.802000)

updates: Integration of new information about the health benefits, impact on industries, and challenges of weight loss drugs

  • ➔
  • ➔
Version 0.02 (2023-12-17 09:07:12.875000)

updates: Novo Nordisk's obesity drug market gains expected to slow in 2024

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.01 (2023-11-20 07:20:33.924000)

updates: Updated with information about weight loss drugs dominating Q3 earnings calls

  • ➔
  • ➔
  • ➔
Version 0.0 (2023-11-19 11:52:10.584000)

updates:

  • ➔
  • ➔